Biofrontera AG – NASDAQ:BFRA
Founder-led company
Biofrontera AG stock price today
$2.67
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 3 hours
Biofrontera AG stock price monthly change
-18.60%
month
Biofrontera AG stock price quarterly change
-24.58%
quarter
Biofrontera AG stock price yearly change
-56.44%
year
Biofrontera AG key metrics
Market Cap | N/A |
Enterprise value | 70.80M |
P/E | -4.34 |
EV/Sales | 2.52 |
EV/EBITDA | -5.33 |
Price/Sales | 2.29 |
Price/Book | 4.04 |
PEG ratio | 0.08 |
EPS | -0.59 |
Revenue | 27.99M |
EBITDA | -13.26M |
Income | -16.72M |
Revenue Q/Q | 14.13% |
Revenue Y/Y | -15.27% |
Profit margin | -59.75% |
Oper. margin | -42.23% |
Gross margin | 86.85% |
EBIT margin | -42.23% |
EBITDA margin | -47.4% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBiofrontera AG stock price history
Biofrontera AG stock forecast
Biofrontera AG financial statements
| Dec 2020 | 9.51M | -2.12M | -22.28% |
|---|---|---|---|
| Mar 2021 | 5.47M | -4.87M | -89.01% |
| Jun 2021 | 7.61M | -3.99M | -52.46% |
| Sep 2021 | 5.37M | -5.73M | -106.56% |
| 2021-05-11 | -0.25 | -0.22 |
|---|---|---|
| 2021-11-25 | -0.22 | -0.24 |
| Dec 2020 | 56390000 | 49.01M | 86.92% |
|---|---|---|---|
| Mar 2021 | 77076000 | 51.44M | 66.74% |
| Jun 2021 | 72634000 | 51.06M | 70.3% |
| Sep 2021 | 69228000 | 53.33M | 77.04% |
| Sep 2018 | -4.94M | -199K | 26.9K |
|---|---|---|---|
| Dec 2018 | -1.65M | -135.4K | 92.5K |
| Jun 2020 | 0 | 0 | 0 |
| Sep 2020 | 0 | 0 | 0 |
Biofrontera AG alternative data
| Aug 2023 | 149 |
|---|---|
| Sep 2023 | 149 |
| Oct 2023 | 149 |
| Nov 2023 | 149 |
| Dec 2023 | 149 |
| Jan 2024 | 149 |
| Feb 2024 | 149 |
| Mar 2024 | 149 |
| Apr 2024 | 149 |
| May 2024 | 149 |
| Jun 2024 | 149 |
| Jul 2024 | 149 |
Biofrontera AG other data
| Quarter | Transcript |
|---|---|
| Q3 2021 18 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 20 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q4 2020 13 Apr 2021 | Q4 2020 Earnings Call Transcript |
| Q2 2020 27 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Hermann Lubbert Ph.D. (1956) Co-Founder & Chief Executive Officer | $470,420 |
-
What's the price of Biofrontera AG stock today?
One share of Biofrontera AG stock can currently be purchased for approximately $2.67.
-
When is Biofrontera AG's next earnings date?
Unfortunately, Biofrontera AG's (BFRA) next earnings date is currently unknown.
-
Does Biofrontera AG pay dividends?
No, Biofrontera AG does not pay dividends.
-
What is Biofrontera AG's stock symbol?
Biofrontera AG is traded on the NASDAQ under the ticker symbol "BFRA".
-
What is Biofrontera AG's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Biofrontera AG?
Shares of Biofrontera AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Biofrontera AG's key executives?
Biofrontera AG's management team includes the following people:
- Dr. Hermann Lubbert Ph.D. Co-Founder & Chief Executive Officer(age: 69, pay: $470,420)
-
Is Biofrontera AG founder-led company?
Yes, Biofrontera AG is a company led by its founder Dr. Hermann Lubbert Ph.D..
-
How many employees does Biofrontera AG have?
As Jul 2024, Biofrontera AG employs 149 workers.
-
When Biofrontera AG went public?
Biofrontera AG is publicly traded company for more then 7 years since IPO on 14 Feb 2018.
-
What is Biofrontera AG's official website?
The official website for Biofrontera AG is biofrontera.com.
-
How can i contact Biofrontera AG?
Biofrontera AG can be reached via phone at +49 214 876320.
Biofrontera AG company profile:
Biofrontera AG
biofrontera.comExchange:
NASDAQ
Full time employees:
149
Industry:
Biotechnology
Sector:
Healthcare
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Hemmelrather Weg 201
Leverkusen, 51377
Leverkusen, 51377
CIK: 0001712641
ISIN: US09075G1058
CUSIP: 09075G105
